Two members of the angiopoietin-like family of proteins, angiopoietin-like protein 3 (ANGPTL3) and 4 (ANGPTL4) have been shown to play important roles in modulating liproprotein metabolism in the body. Both proteins were found to suppress lipoprotein lipase (LPL) activity in vitro as well as in vivo. However, their mechanisms of inhibition remain poorly understood. Using enzyme kinetic analysis with purified recombinant proteins, we have found key mechanistic differences between ANGPTL3 and ANGPTL4. ANGPTL3 reduces LPL's catalytic activity but does not significantly alter its self-inactivation rate. In contrast, ANGPTL4 suppresses LPL by accelerating the irreversible inactivation of LPL. Furthermore, heparin is able to overcome the inhibitory effect of ANGPTL3 on LPL but not that of ANGPTL4. Site-directed mutagenesis demonstrated the critical function of residue Glu40 in ANGPTL4. On the other hand, when cysteine residues involved in disulfide bond formation were mutated to serines, ANGPTL4 retained its activity. Taken together, our data provided a more detailed view of the structure and mechanisms of these proteins. The findings that ANGPTL3 and ANGPTL4 inhibit LPL activity through distinct mechanisms indicate the two proteins play unique roles in modulation of lipid metabolism in vivo.
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Lipoprotein lipase (LPL) is an essential enzyme that catalyzes the hydrolysis of triglycerides to generate free fatty acids and monoacylglycerol (see ref. (1, 2) for review). It is synthesized and secreted by adipocytes, macrophages and muscle cells, and then bound to the vascular endothelium by heparin sulfate proteoglycans and glycosylphosphatidylinositolanchored high-density lipoprotein-binding protein 1 (GPIHBP1), a protein discovered recently (3, 4) . LPL anchored as such releases free fatty acids and monoacylglycerol from triglyecrides carried by chylomicron and very-low-density lipoprotein (VLDL) particles (5) (6) (7) (8) (9) , and thus plays a major role in lipid metabolism. LPL-deficient subjects have severe hypertriglyceridemia and increased risk of arteriosclerosis (10) . In contrast, subjects with slightly increased LPL activity were found to have lower triglyceride levels and decreased risk of cardiovascular diseases (11) .
It is well known that LPL is rapidly inactivated in vivo, but the underlying mechanism is unknown (12, 13) . Recently, two secreted proteins were found to inhibit LPL activity both in vitro and in vivo. These two proteins, known as angiopoietin-like protein 3 and 4 (ANGPTL3 and ANGPTL4) are members of the angiopoietin-like protein family (14) (15) (16) (17) . They share 31% overall sequence homology, with an N-terminal domain containing a coiled-coil region, and a C-terminal fibrinogen-like domain which is cleaved off in vivo (16, 18) . Both proteins are found to inhibit LPL activity in vitro (16, 18) . Overexpression of ANGPTL3 and ANGTPL4 in mice led to extremely high blood levels of triglycerides and cholesterol (15, (19) (20) (21) . Knockout of either gene in mice resulted in much lower blood levels of these lipids (14, (17) (18) (19) (22) (23) (24) . Furthermore, post-heparin plasma LPL activity was significantly elevated in mice lacking ANGPTL3 (fed state) or ANGPTL4 (both fed and fasted states) (6, 16, 23) , indicating their importance in regulating LPL activity in vivo. The two genes were also found to play major roles in lipid metabolism in human. A variant of ANGPTL4, Glu40→Lys, was found to be associated with significantly lower plasma triglyceride levels and higher HDL levels (25); ANGPTL3 is also linked to atherosclerosis (26) . The human and mouse data strongly suggest that these two proteins modulate LPL in vivo, presumably through inhibition of LPL activity.
The exact mechanism of how ANGPTL3 and ANGPTL4 suppress LPL is unknown. In both proteins, the N-terminal domains are cleavage products in vivo and sufficient to inhibit LPL in vitro and in vivo (16, 18, 27) . Purified LPL exists in two forms, dimeric and monomeric, with the dimer being the only active form (28) . Detailed kinetic analysis showed that the dimer molecules can self-inactivate, possibly via a rapid exchange with its monomeric subunits and irreversible formation of inactive monomers and aggregates (13, 29) . One study showed ANGPTL4 was able to accelerate dissociation of active LPL dimers into monomers and therefore reduce LPL activity (16) . It was suggested that the N-terminal domain of ANGPTL4 acted like a catalyst to affect LPL in less than equimolar ratios. However it was not yet known how its homolog, ANGPTL3, would behave with LPL. Earlier comparative studies between ANGPTL4 and ANGPTL3 focused on the differences in expression levels and transcription regulation (30) . Given the importance of these proteins in lipid metabolic regulation, we carried out quantitative analysis to examine the inhibitory properties of recombinant ANGPTL3, ANGPTL4 and relevant mutants. The intriguing differences in the inhibition mechanisms of ANGPTL3 and ANGPTL4 to LPL will hopefully provide insight into their structural characteristics and shed light on the in vivo functional distinctions of these two proteins.
Experimental Procedures
Expression and purification of LPL, ANGPTL3 and ANGPTL4 and mutants -The full-length coding sequence of human LPL with a C-terminal FLAG-tag was cloned into the vector pIRESpuro and transfected into HEK293 cell. Bulk stable cells were selected at 2.4 μg/ml of puromycin, and grown in serum-free media. The media was collected after 3 days of cell growth. Glycerol and NaCl were added into the media to a final concentration of 25% and 0.4 M, respectively, which was then stored at -20 o C. Purification of human LPL from the media was carried out essentially as described previously (31) . Active fractions were pooled, aliquoted, and stored at -80 o C.
N-terminal regions encoding amino acids 20 to 243 of human ANGPTL3 and the sequence encoding amino acids 26 to 176 of human ANGPTL4 were cloned into pET24 with a cleavable His-tag at the N-terminus. Three ANGPTL4 mutants, glutamate-40 to lysine (E40K), cysteine-76 and cysteine-80 to serine (C76S/C80S), and E40K/C76S/C80S were constructed with the same vector. The expression plasmids were transformed into BL21/DE3, and the respective proteins were purified with Ni-NTA followed by a Hi-Load 16/60 Superdex 200 column. The fractions were assayed for their activity to inhibit LPL.
Lipoprotein Lipase Activity Assays -In vitro LPL activity assays were carried out using 1,2-Odilauryl-rac-glycero-3-glutaric acid-(6'-methylresorufin) ester (DGGR) as a fluorescent substrate (Sigma) (32) . Purified bovine milk LPL (Sigma) or human recombinant LPL was used. The assays were performed in 96-well plates at 50 μl per well with 18 μM of DGGR in a reaction buffer consisting of 20 mM sodium phosphate and 0.4% Triton X-100 at pH 8.1. The reactions were jumpstarted by adding LPL to the reaction mixture to a final concentration of 10 nM, and the fluorescence signal of the DGGR cleavage product was immediately monitored for 90 min on a TECAN Ultra 384 plate reader (Tecan Systems, San Jose, CA) at an excitation wavelength of 535 nm and emission wavelength of 612 nm.
The effects of ANGPTL3 or ANGPTL4 on LPL activity were measured in the above assay with the addition of ANGPTL3 to a final concentration ranging from 0 to 2 μM, or ANGPTL4 from 0 to 40 nM, based on monomer molecular weights of 20 kDa. In addition, the effects of heparin against ANGPTL3 or ANGPTL4 were tested in a similar method, with various concentrations of ANGPTL3, ANGPTL4 and heparin up to 2 μM, 40 nM, and 80U/ml, respectively.
The progress curves of DGGR hydrolysis by LPL, with or without ANGPTL3/4 were analyzed using the equation that describes the irreversible inactivation of an enzyme (33,34): P(t) = P ∞ · (1-exp(-k · t) + C 0 , where t is the reaction time, P(t) correlates to the fluorescence intensity by the amount of product at time t, C 0 accounts for the background fluorescence signal, k is the fitted apparent rate constant for the onset of LPL inactivation, and P ∞ is the final total product amount. The inactivation properties of either ANGPTL3 or ANGPTL4 were assessed by the plot of the fitted values of k as a function of ANGPTL3/4 concentration. The maximum span of Δk correlated with the inactivation efficiency of either protein. The protein concentration at ½×k max also contributed to the potency of the inactivator (35) .
RESULTS
The inhibitory actions of ANGPTL3 and ANGPTL4 were first compared in the in vitro LPL activity assay. Both ANGPTL3 and ANGPTL4 lowered the activity of LPL in a dose-dependent manner ( Fig. 1A and 1B) . However, ANGPTL4 inhibited LPL more potently than ANGPTL3 did. The IC 50 value (based on end-point product concentrations) for ANGPTL4 is approximately 100 times lower than that of ANGPTL3 (2 nM vs 180 nM). The constantly decreasing LPL activity has presented a challenge to study the mechanism of inhibition in a quantitative manner (16) . Using non-linear regression analysis on their progress curves, LPL-inactivating abilities of ANGPTL3 and ANGPTL4 could be characterized by the apparent inactivation rate constant, k, and its relationship with the concentrations of these two proteins ( Fig. 1C and 1D ). ANGPTL4 was much more potent at accelerating LPL inactivation than ANGPTL3, as indicated by the differences in the maximum span of Δk (9.3×10 -4 s -1 vs. 2.9×10 -4 s -1 , for ANGPTL4 and ANGPTL3, respectively) and inactivation potency (concentration at ½×k max being 2 nM vs. 903 nM, for ANGPTL4 and ANGPTL3, respectively). On the other hand, it is important to point out that despite the limited ability of ANGPTL3 to accelerate the inactivation of LPL, it was able to suppress LPL by inhibiting its initial activity, as seen in Fig. 1B .
To further confirm that ANGPTL4 is more effective than ANGPTL3 in inactivating LPL, we pre-incubated ANGPTL4 or ANGPTL3 with LPL for different durations before adding the substrate and measured the decrease in LPL activity due to its exposure to the proteins. Consistent with the results in Fig. 1A and 1C , LPL was quickly inactivated by ANGPTL4 during pre-incubation in the absence of the substrate, as seen in the decrease of the initial LPL reaction rates as a function of pre-incubation times (normalized by the initial reaction rates at pre-incubation time = 0) (Fig. 1E) . In contrast, incubating LPL with ANGPTL3 did not significantly accelerate LPL inactivation beyond its self-inactivation (Fig. 1F) , even though it inhibited LPL initial activity at zero pre-incubation time when the substrate was added (see inset of Fig. 1F ). Taken together, the data indicate that there are the two major factors contributing to LPL suppression, i.e., acceleration of its inactivation, as in the case of ANGPTL4, and suppression of its catalytic activity in the presence of substrates, as with ANGPTL3.
In the plasma, heparin plays an important role of anchoring LPL via a strong interaction between the poly-anionic charges of heparin and the positively-charged clusters on the LPL surface (36). The affinity of heparin is much higher for active LPL dimers than for inactive monomers or aggregates. Aside from presenting active LPL to the incoming lipoprotein particles, whether heparin played a role in stabilizing LPL or delaying its inactivation was largely unknown. Thus we probed the biochemical influence of heparin to evaluate its stabilizing effects on LPL and its potential interaction with ANGPTL3 or ANGPTL4. We found that, in the absence of ANGPTL3 or ANGPTL4, heparin resulted in a slightly higher level of overall product formation ( Fig. 2A-B) . Interestingly, heparin demonstrated markedly different effects on ANGPTL3, compared to ANGPTL4, for LPL inhibition. Whereas heparin could rescue LPL from the inhibition of ANGPTL3 at a concentration as low as 0.8 U/ml, heparin was unable to reverse the effects of ANGPTL4 on LPL at concentrations up to 10 U/ml ( Fig. 2A-B) . Using biochemical analysis to evaluate the apparent inactivation constant, k, as a function of heparin concentrations (Fig. 2C-D) , we were able to gain some insights to the observed effects of heparin on ANGPTL3 and ANGPTL4. As demonstrated by the small decrease in LPL self-inactivation rate (solid curve in Fig. 2C ), heparin only had a small stabilizing effect on LPL. This resulted in the slightly higher LPL product formation by heparin alone.
Furthermore, due to its limited ability to delay LPL's self-inactivation, heparin was unable to offset the inactivation-accelerating effects of ANGPTL4 (Fig. 2C) ; on the other hand, heparin was able to rescue LPL from ANGPTL3 since ANGPTL3 did not significantly accelerate LPL inactivation (Fig. 2D) . These findings suggest that heparin had a limited role in stabilizing the bound LPL active dimers, pointing to the main purpose of heparin molecules as presenters of the active LPL molecules, possibly in a favorable orientation to trap the substrate-containing lipoprotein particles.
Despite the important inhibitory actions of ANGPTL3 and ANGPTL4, the binding motifs between LPL and ANGPTL3/4 have not been elucidated. The lack of X-ray crystal structure has limited our understanding of the dimer formation of LPL. Based on molecular biology and modeling efforts, the most recent estimation was that LPL formed a dimer in a head-to-tail, side-by-side fashion with the catalytic domains exposed (9, 29, 36) . Recent discoveries of ANGPTL4 singlenucleotide polymorphism variants in human subjects provided insight to the possibly critical regions on ANGPTL4 that interact with LPL. One variant, in particular, E40K, was found to be associated with significant decrease of plasma triglyceride levels (25) . We found that this single point mutation caused a significant loss of ANGPTL4's inactivating effects on LPL (Fig. 3A-B) . Compared to wild-type ANGPTL4, the estimated Δk max value for the E40K mutant decreased to 2.7 ×10 -4 s -1 . As a result, the IC 50 of ANGPTL4 based on LPL end-point product formation increased more than 100-fold, from about 3 nM (WT) to over 300 nM (E40K) (Fig.  3C) . Our results demonstrated that the E40K mutation led to a near total loss of ANGPTL4 activity, and that this residue played a key role in the interaction between ANGPTL4 and LPL, offering the first biochemical explanation for the decreased TAG levels in subjects with this polymorphism.
In our effort to gain further understanding of the key residues that contribute to the activity of ANGPTL4, we also investigated the cysteine residues (C76 and C80) that were thought to be responsible for forming oligomeric ANGPTL4 and its activity via intermolecular disulfide bond (27, 37) . Instead of changing to alanine as studied by Ge et al (27) , we generated a double mutant C76S/C80S in the ANGPTL4 N-terminal domain, and a triple mutant C76S/C80S/E40K, both of which have no remaining cysteines. In side-byside comparisons with wild-type ANGPTL4 and the E40K mutant, the replacement of cysteine residues by serines did not alter the activity of ANGPTL4 (Fig. 3C) . The double mutant C76S/C80S showed comparable potency as the wildtype protein, and the triple mutant C76S/C80S/E40K was similar to the E40K mutant. In addition, our gel filtration analysis showed that the wild-type ANGPTL4 and C76S/C80S mutant were in similar oligomeric states, with both proteins giving an apparent MW of 120 kDa, suggesting hexamer formation based on a monomer MW of 20 kDa (Fig. 3D) . Our results are consistent with earlier findings that ANGPTL4 forms oligomers (27, 37) . However, we found that when the cysteine residues in the coiled-coil domain are converted to serines, the oligomer configuration of the protein remained unchanged, indicating that intermolecular or intramolecular disulfide bond is not critical to ANGPTL4 oligomer formation. The N-terminal domain of ANGPTL3 does not contain any cysteines but can still form oligomers (data not shown), further corroborating the conclusion that disulfide bond is not essential. The more drastic mutation of cysteines to alanines in the earlier study may have caused both the loss of activity and change in the oligomeric states of ANGPTL4.
DISCUSSION
We have taken a quantitative biochemical approach to dissect the functions of ANGPTL3 and ANGPTL4 as LPL-inhibiting macromolecules and revealed the mechanistic differences between these two proteins for the first time. Based on such differences, a simple, schematic model is proposed in Fig. 4 to describe the interactions between LPL and its inhibitors. In this model, heparin-bound LPL is quickly inactivated by ANGPTL4. ANGPTL3, on the other hand, mainly exhibits reversible inhibition of the catalytic activity of LPL. This important distinction is further highlighted by the differential abilities of heparin to rescue LPL from these proteins. While heparin was observed to protect LPL from ANGPTL3 at relatively low concentrations, possibly via competitive binding, it was not able to deter the inactivating effects by ANGPTL4. Our conclusions are based on data derived from the fluorescent substrate DGGR, which, despite being an artificial substrate, makes it possible to carry out detailed real-time kinetic analysis as studied previously (32, 38) . Future efforts to develop a sensitive kinetic assay with native triglyceride molecules will likely strengthen the mechanistic understanding of these proteins. In addition, while it is beyond the scope of our current study, it would be interesting to utilize a similar approach to evaluate the involvement, if any, of GPIHBP1 in modulating ANGPTL3 or ANGPTL4.
Our in vitro biochemical study results also shed some light on the in vivo mechansims of these proteins. Plasma triglyceride levels, as modulated by LPL activity, fluctuate with various nutritional and hormonal states to meet the physiological needs of the body. ANGPTL4, originally identified as a fasting-induced adipose factor, is mainly expressed in adipocytes and is dramatically up-regulated in the fasted state (6) . Under fasting conditions, it is critical for the adipose tissue to halt fatty acids uptake from the circulation and to start releasing fatty acids. ANGPTL4's unique inactivating property as well as excellent potency against LPL is essential to quickly disable LPL. Upon refeeding, ANGPTL4 expression is quickly down-regulated, and new LPL is synthesized and stays active. On the other hand, ANGPTL3 is mostly produced in the liver and released into the circulation, and its expression does not appear to change with feeding status. Concentration of ANGPTL3 in the blood is much higher than that of ANPTL4, which compensates its lower potency. A major role of ANGPTL3 may be a partial suppression of LPL during the fed state. Regulation of ANGPTL3 expression, such as by LXR and the thyroid receptor, allows the body to modulate LPL activity at the systemic level. The physiological significance of such suppression is, however, not clear (30) . Recent findings that ANGPTL3 can also inhibit endothelial lipase (EL) pointed to another functional role of ANGPTL3 (24) . It would be interesting to compare the inhibitory potency and mechanism for ANGPTL3 toward LPL and EL in a future study.
Further insight to the roles of ANGPTL3 and ANGPTL4 requires in-depth structural characterization of these two proteins in their interaction with LPL. Due to stability issues and oligomeric formation, this has been a challenge. Our attempt to understand ANGPTL3 and ANGPTL4 at the sub-molecular level revealed that key residues such as Glu40 in ANGPTL4 contributed to the inactivating properties of the protein, while cysteine residues that could be involved in disulfide bond formation did not affect the activity or the oligomeric conformation of the protein. Given the important biological roles of LPL in lipid metabolisms and its regulation by ANGPTL3 and ANGPTL4, our biochemical characterizations not only presented a mechanistic overview of these proteins' actions, but also offered a pharmacological platform for evaluating potential antibodies and small molecules in the discovery of therapeutic agents to treat dyslipidemia. Gel filtration analysis of wildtype ANGPTL4 and its C76S/C80S mutant. The legend for each elution profile is shown in the panel. The identical elution times for the C76S/C80S mutant with and without His-tag indicate that the 6×His tag had no effect on the oligomer formation of these proteins. Protein standards with the following molecular weights were used: A, 670 kDa; B, 158 kDa; C, 44 kDa; D, 17 kDa. 
